Physician profile
David B Arkin
NPI 1891865937
$15,123.68
in general payments reported to CMS, 2019-2025
65 companies · $2,471 in 2025
The $2,471 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,845 · 2020: $887 · 2021: $1,560 · 2022: $1,897 · 2023: $2,451 · 2024: $3,013 · 2025: $2,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,924 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,923.84 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,889.70 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $1,775.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,348.92 | 2019-2025 | Tepezza, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $1,258.64 | 2019-2025 | |
| Lilly USA, LLC | $751.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Insulet Corporation | $714.90 | 2019-2025 | Omnipod |
| Dexcom, INC. | $680.82 | 2020-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $510.53 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $463.40 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $432.21 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $350.26 | 2019-2022 | |
| Beta Bionics, INC. | $346.10 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $337.34 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.58 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Abbvie INC. | $292.46 | 2019-2025 | Synthroid |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Arkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.